Trials / Sponsors / Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Academic / Other · 69 registered clinical trials — 34 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | 2026-03-18 |
| Recruiting | cfMSC Therapy for Diabetes Type II Diabetes Mellitus | Phase 1 / Phase 2 | 2026-03-16 |
| Recruiting | cfMSC Stem Cell Therapy Targeting COPD Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | 2026-03-10 |
| Recruiting | DLL3 CAR-T Therapy Targeting Brain Tumors Glioblastoma of Cerebellum | Phase 1 / Phase 2 | 2025-09-10 |
| Recruiting | NG2 and DLL3 CAR-T Cells Targeting Melanoma Melanoma | Phase 1 / Phase 2 | 2025-09-01 |
| Recruiting | Combination Immunotherapy Targeting Melanoma Melanoma | Phase 1 / Phase 2 | 2025-08-31 |
| Recruiting | IT and IV Lentiviral Gene Therapy for X-ALD X-linked Adrenoleukodystrophy | N/A | 2025-08-31 |
| Recruiting | Combination CAR-T Cell Therapy Targeting Hematological Malignancies B-cell Malignancies | Phase 1 / Phase 2 | 2025-08-01 |
| Recruiting | Intervention of Bladder Cancer by CAR-T Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | 2025-08-01 |
| Recruiting | Prostate Cancer Vaccines Prostate Cancer Indications | Phase 1 / Phase 2 | 2025-06-15 |
| Recruiting | Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD Metachromatic Leukodystrophy (MLD) | N/A | 2025-06-01 |
| Recruiting | Direct Lentiviral Injection Gene Therapy for MLD Metachromatic Leukodystrophy (MLD) | N/A | 2025-05-31 |
| Recruiting | Genetically Modified T Cells Against Ovarian Cancer Ovarian Cancer | Phase 1 / Phase 2 | 2025-05-01 |
| Recruiting | A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Maligna B-cell Malignancies | Phase 1 / Phase 2 | 2025-05-01 |
| Recruiting | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 Solid Tumor | Phase 1 / Phase 2 | 2025-05-01 |
| Enrolling By Invitation | Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders Immune Related Disorder, Tissue Damage | Phase 1 | 2025-01-01 |
| Recruiting | SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection SCID, X-Linked | Phase 1 / Phase 2 | 2024-06-30 |
| Recruiting | Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID) | N/A | 2024-06-30 |
| Recruiting | Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells Autoimmune Diseases | Phase 1 / Phase 2 | 2024-05-15 |
| Recruiting | Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | 2024-05-11 |
| Recruiting | Engineered Dendritic Cell Vaccines for Multiple Myeloma Multiple Myeloma or Plasmacytoma | Phase 1 | 2024-05-11 |
| Recruiting | Universal 4SCAR7U Targeting CD7-positive Malignancies T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia | Phase 1 | 2023-10-31 |
| Recruiting | 4SCAR19U T Cells Targeting B Cell Malignancies B Cell Malignancies | Phase 1 | 2023-10-31 |
| Recruiting | Universal CAR-T Cells Targeting Multiple Myeloma Multiple Myeloma in Remission | Phase 1 | 2023-10-31 |
| Recruiting | Universal CAR-T Cells Targeting AML Acute Myeloid Leukemia | Phase 1 | 2023-10-31 |
| Recruiting | CAR-T Cells Targeting Autoimmune Diseases Autoimmune Diseases | Phase 1 / Phase 2 | 2022-07-31 |
| Recruiting | CD19/70 Bi-specific CAR-T Cell Therapy B Cell Malignancies | Phase 1 / Phase 2 | 2022-06-30 |
| Recruiting | GD2/PSMA Bi-specific CAR-T Cell Therapy Solid Tumor | Phase 1 / Phase 2 | 2022-06-30 |
| Recruiting | CD19/79b Bi-specific CAR-T Cell Therapy B Cell Malignancies | Phase 1 / Phase 2 | 2022-06-30 |
| Recruiting | CD19/22 Bi-specific CAR-T Cell Therapy B Cell Malignancies | Phase 1 / Phase 2 | 2022-06-30 |
| Recruiting | PSMA/CD70 Bi-specific CAR-T Cell Therapy Cancer Disease | Phase 1 / Phase 2 | 2022-06-30 |
| Recruiting | GD2/CD56 Bi-specific CAR-T Cell Therapy Malignant Disease | Phase 1 / Phase 2 | 2022-06-30 |
| Recruiting | GD2/CD70 Bi-specific CAR-T Cell Therapy Cancer Disease | Phase 1 / Phase 2 | 2022-06-30 |
| Unknown | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL T-Cell Acute Lymphoblastic Leukemia | Phase 1 | 2022-03-15 |
| Unknown | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL B-Cell Acute Lymphoblastic Leukemia | Phase 1 | 2022-03-01 |
| Unknown | 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma Neuroblastoma | Phase 1 / Phase 2 | 2020-11-18 |
| Unknown | Combination Immunotherapy Targeting Sarcomas Sarcoma, Osteoid Sarcoma, Ewing Sarcoma | Phase 1 / Phase 2 | 2020-07-01 |
| Unknown | Multi-4SCAR-T Therapy Targeting Breast Cancer Breast Cancer | Phase 1 / Phase 2 | 2020-06-01 |
| Unknown | 4SCAR-CD44v6 T Cell Therapy Targeting Cancer Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | 2020-06-01 |
| Unknown | Lentiviral FIX Gene Therapy Hemophilia B | Phase 1 | 2020-06-01 |
| Unknown | Lentiviral FVIII Gene Therapy Hemophilia A | Phase 1 | 2020-06-01 |
| Unknown | 4SCAR-T Therapy Post CD19-targeted Immunotherapy CD19 Negative B-cell Malignancies | Phase 1 / Phase 2 | 2020-06-01 |
| Unknown | Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 Solid Tumor | Phase 1 / Phase 2 | 2020-06-01 |
| Unknown | Multi-CAR-T Cells Targeting B Cell Lymphomas B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | 2020-06-01 |
| Unknown | Immunity and Safety of Covid-19 Synthetic Minigene Vaccine Pathogen Infection Covid-19 Infection | Phase 1 / Phase 2 | 2020-03-24 |
| Unknown | Safety and Immunity of Covid-19 aAPC Vaccine Treat and Prevent Covid-19 Infection | Phase 1 | 2020-02-15 |
| Unknown | PSMA-specific CAR-T Cell Therapy PSMA Positive Tumors or Tumor Tissues | Phase 1 / Phase 2 | 2020-01-01 |
| Unknown | Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis Cancer | Phase 1 / Phase 2 | 2019-09-01 |
| Unknown | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2019-09-01 |
| Unknown | Multiple CAR-T Cell Therapy Targeting AML Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2019-08-01 |
| Unknown | CAR-T Immunotherapy Targeting CD19- ALL B-cell Leukemia | Phase 1 / Phase 2 | 2019-07-15 |
| Unknown | Immune Modulatory DC Vaccine Against Brain Tumor Diffuse Intrinsic Pontine Glioma or Glioblastoma | Phase 1 | 2019-03-31 |
| Unknown | Immunotherapy Treating GI Cancer Cancer | Phase 1 / Phase 2 | 2018-07-01 |
| Unknown | Lentiviral Gene Therapy for CGD Chronic Granulomatous Disease | N/A | 2018-07-01 |
| Unknown | Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells Cancer | Phase 1 / Phase 2 | 2018-07-01 |
| Unknown | Antigen-specific T Cells Against Lung Cancer Lung Cancer | Phase 1 / Phase 2 | 2017-12-15 |
| Unknown | FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vect Fanconi Anemia | N/A | 2017-12-01 |
| Unknown | Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas Sarcoma, Osteoid Sarcoma, Ewing Sarcoma | Phase 1 / Phase 2 | 2017-12-01 |
| Unknown | Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector Beta-Thalassemia | N/A | 2017-12-01 |
| Suspended | Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors Ovarian Cancer | Phase 1 / Phase 2 | 2017-12-01 |
| Unknown | Engineered Immune Effectors Against Cervical Cancer Cervical Cancer | Phase 1 / Phase 2 | 2017-11-15 |
| Unknown | Intervention of CAR-T Against Cervical Cancer Cervical Cancer | Phase 1 / Phase 2 | 2017-11-15 |
| Withdrawn | Intervention of Engineered Immune Effector T Cells Against Lung Cancer Lung Cancer, NSCLC | Phase 1 / Phase 2 | 2017-11-15 |
| Unknown | HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV Human Papilloma Virus | Phase 1 / Phase 2 | 2017-11-15 |
| Unknown | Engineered Immune Effectors Against Ovarian Cancer Ovarian Cancer | Phase 1 / Phase 2 | 2017-11-15 |
| Unknown | Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections Pathogen Infection, EBV Infection, CMV Infection | Phase 1 / Phase 2 | 2017-07-15 |
| Unknown | Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2017-07-15 |
| Unknown | Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2017-07-15 |
| Enrolling By Invitation | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme Glioblastoma Multiforme of Brain, Brain Cancer | Phase 1 | 2017-05-31 |